股价波动
Search documents
华仕伯股价单日大涨近11%,创近期新高
Jing Ji Guan Cha Wang· 2026-02-12 14:24
股价上涨的主要背景因素包括:所属板块整体表现强劲,当日,华仕伯所属的美股油气设备与服务板块 整体上涨4.58%,显示出行业层面的积极情绪。近期股价波动较大,华仕伯股价在近期经历了较大波 动。在2月9日,其股价单日大幅上涨34.31%,尽管在2月10日出现回调下跌4.78%,但2月11日的上涨使 得其5日累计涨幅达到51.90%。这种剧烈的价格变动通常反映了市场情绪的快速转换或对特定消息的重 新定价。 以上内容基于公开资料整理,不构成投资建议。 经济观察网华仕伯(VAL.N)股价在2026年2月11日出现显著上涨,收盘价为88.42美元,单日涨幅达 10.79%。该价格创下了公司近期股价的高点。 股票近期走势 ...
巴拉德动力系统股价震荡,机构评级普遍谨慎
Jing Ji Guan Cha Wang· 2026-02-12 14:05
Group 1 - The core focus of the news is on the significant stock price volatility of Ballard Power Systems (BLDP.OQ) and the cautious stance of institutional ratings during the week of February 5 to 11, 2026, with no new financial reports or major contracts disclosed [1] - The stock price experienced a high-frequency fluctuation with a range of 9.01%, showing a cumulative decline of 4.50% over the past five days and a year-to-date drop of 16.54%, underperforming the electrical equipment parts sector and the Nasdaq index [2] - Institutional ratings have tightened, with no "buy" recommendations among 13 institutions, 77% giving "hold," and 23% suggesting "reduce or sell," with a target average price of $2.62, indicating a 23.58% premium over the current stock price [3] Group 2 - The earnings forecast remains under pressure, with an expected earnings per share of -$0.078 for Q4 2025, although this reflects a year-on-year improvement of 38.10%, indicating market observation regarding cost control effectiveness [3] - Attention is required on the progress of achieving positive cash flow and the capacity assessment dynamics of the Shanghai membrane electrode factory [3]
星际时尚股价剧烈波动,财务表现不佳引关注
Jing Ji Guan Cha Wang· 2026-02-12 13:54
Stock Performance - The stock of Star Fashion (STFS.us) experienced significant volatility in January 2026, with a notable drop on January 5, closing at $0.090 per share and a trading volume of 566,456 shares, resulting in a turnover rate of 1.67% [2] - Prior to the drop on January 5, the stock also saw a decline on January 3, indicating a trend of instability [2] Financial Performance - The latest financial report indicates that the company generated a revenue of $16.74 million, but reported a net loss of $18.13 million, resulting in an earnings per share of -$1.30 and a low gross margin [3] - Currently, no investment recommendations have been provided by any institutions regarding the stock [3] Market Context - The stock's volatility is linked to the overall performance of the advertising and marketing industry, although the company has not released specific announcements regarding the reasons for these fluctuations [2]
韩国电力近期股价波动及财务表现回顾
Jing Ji Guan Cha Wang· 2026-02-12 13:33
Stock Performance - On January 7, 2026, Korea Electric Power's stock price experienced a sharp decline of 5.08%, closing at $16.99 per share, with an intraday volatility of 2.68% [1] - At that time, 71% of brokerage firms rated the stock as a buy, with no sell recommendations [1] Financial Status - As of January 27, 2026, the company's latest financial data indicated a trailing twelve months (TTM) earnings per share of 2,925.00 KRW, a current ratio of 0.48, and a return on equity (ROE) of 8.43% [2] - These metrics reflect the company's operational status as of the specified date [2] - Regular events such as quarterly earnings reports should be confirmed through official announcements from Korea Electric Power [2]
赛特新材股价波动,核心技术人员离职
Jing Ji Guan Cha Wang· 2026-02-12 10:51
经济观察网 近7天,赛特新材股价呈现波动走势,区间涨幅为16.67%,振幅25.91%,市场交易活跃。2 月12日,股价下跌2.64%,收盘报23.59元,主力资金净流出437.65万元。 以上内容基于公开资料整理,不构成投资建议。 近期事件 2月6日,公司公告核心技术人员余锡友因个人原因离职,不再担任任何职务。公司表示,其离职已完成 工作交接,相关专利所有权归属公司,不会对技术研发和核心竞争力产生实质性影响。 ...
新经典股价上涨5.18%,前三季度净利润同比下降46.59%
Jing Ji Guan Cha Wang· 2026-02-12 10:51
Stock Performance - The stock price of New Classics increased by 5.18% on February 10, 2026, closing at 20.51 CNY per share, with a total market capitalization of approximately 3.163 billion CNY. The trading volume for the day was 66.5628 million CNY, with a turnover rate of 2.15% [2]. Financial Performance - The company's Q3 2025 report indicates that revenue for the first three quarters was 475 million CNY, a year-on-year decrease of 25.65%. The net profit attributable to shareholders was 67.794 million CNY, down 46.59% year-on-year. In Q3 alone, revenue was 160 million CNY, a decline of 13.74% year-on-year, with a net profit of 20.9177 million CNY, down 41.73% year-on-year. Additionally, in Q1 2025, revenue decreased by 33.12% year-on-year, and net profit fell by 49.53% year-on-year [3]. Institutional Holdings - As of Q3 2025, Jiashi Fund's Jiashi New Consumption Stock A held 1.6651 million shares of New Classics, accounting for 1.08% of the circulating shares. Additionally, the招商 Fund's 招商优质成长混合 (LOF) held 771,300 shares, representing 0.5% of the circulating shares [4]. Financial Condition - The Q3 2025 report shows that accounts receivable accounted for a high proportion of net profit, reaching 102.87%, indicating a need to monitor the accounts receivable situation. Analysts generally expect the company's total performance for 2025 to be around 110 million CNY [5].
播恩集团股价波动上涨后回调,2025年业绩预告亏损收窄
Jing Ji Guan Cha Wang· 2026-02-12 10:34
经济观察网播恩集团(001366)近7天股价呈现波动上涨后回调的态势。截至2月12日最新收盘价为 14.87元,较2月5日开盘价累计上涨2.84%,但单日下跌0.93%。其中,2月9日股价表现突出,单日涨幅 达3.29%,成交额7959.01万元,换手率9.49%,显示短期交易活跃。资金流向方面,2月6日主力净流出 113.05万元,但小单资金持续流入,反映市场分歧。整体来看,近7天股价振幅达7.47%。 财报分析 公司2025年度业绩预告显示,预计净利润亏损1400万元至2000万元,较2024年亏损有所收窄,同比改善 幅度达30.35%至51.24%。亏损收窄主要源于营业收入预计同比增长30%-40%,但新工厂产能爬坡、客 户结构转向赊销模式导致应收账款增加等因素拖累利润。2025年三季报已显示营收9.76亿元,净亏损 996.11万元,第三季度单季实现盈利467.92万元,同比大幅增长144.55%。 以上内容基于公开资料整理,不构成投资建议。 近期事件 公司于2026年2月6日召开第一次临时股东大会,可能涉及经营决策事项,但具体议程未公开披露。此 外,股东户数变化引发关注:截至1月31日,股东户数为9 ...
亚虹医药-U股价波动下行,2025年业绩预亏,机构维持买入评级
Jing Ji Guan Cha Wang· 2026-02-12 09:39
Group 1 - The stock price of Yahuang Pharmaceutical-U has shown a downward trend over the past week, with a cumulative decline of 2.67% and a fluctuation of 2.99% [1] - On February 12, the closing price was 12.05 yuan, reflecting a daily decrease of 0.50% [1] - The total trading volume over the past week was approximately 398 million yuan, with an active turnover rate of 1.01% on February 12 [1] Group 2 - The company announced a projected net loss for 2025, with a potential year-on-year increase in losses of 18.00% or a decrease of 1.67% [2] - Expected operating revenue for 2025 is projected to grow by 20.30% to 4.436 billion yuan [2] - Research and development expenses are expected to decrease, with significant progress reported in clinical trials for bladder cancer and ulcerative colitis treatments [2] Group 3 - All institutions have given buy or hold ratings based on data from November and September 2025, indicating a 100% consensus [3] - There have been no significant changes in public sentiment or updates on institutional research and target price information [3]
贝康医疗-B股价波动明显,技术指标短期改善
Jing Ji Guan Cha Wang· 2026-02-12 08:53
Group 1 - The core focus of the market regarding Beikang Medical-B (02170.HK) is on stock price fluctuations and trading data, with no significant events or announcements disclosed in the past week [1] - The stock price experienced a fluctuation range of 10.11%, reaching a high of 2.00 HKD on February 9 and a low of 1.81 HKD on February 5 [1] - As of the close on February 12, the stock price was reported at 1.88 HKD, with a cumulative change of 0.00% over the week [1] Group 2 - On February 12, a net inflow of 69,560 HKD was recorded, indicating that retail investors dominated the trading activity [1] - Technical indicators show that the MACD histogram has turned positive, suggesting an improvement in short-term momentum, although the stock price remains below key moving averages [1] - The narrowing of the Bollinger Bands indicates a decrease in volatility [1]
川网传媒发布业绩预告及股价波动风险提示
Jing Ji Guan Cha Wang· 2026-02-12 08:53
Core Viewpoint - The company is expected to disclose its 2025 annual performance forecast, which will be a significant financial event impacting stock prices [1][2]. Group 1: Performance and Financial Situation - The company announced on January 13, 2026, that it is conducting financial accounting for the year 2025 and will disclose the performance forecast if it meets relevant regulations [2]. - The Q3 report for 2025 indicated a year-on-year revenue growth of 25.44%, while net profit decreased by 16.44% [2]. - The annual report is anticipated to provide more comprehensive performance data, making its release time critical [2]. Group 2: Stock Performance and Market Dynamics - From January 12 to 13, 2026, the company's stock experienced unusual fluctuations due to a cumulative deviation exceeding 30%, prompting a risk warning announcement [3]. - Future significant stock price volatility or changes in industry policies may trigger similar announcements [3].